Clinical Trials
100 trialsA First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
Vividion Therapeutics, Inc.
IMbrella B
Hoffmann-La Roche
Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).
Amgen
An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)
Hoffmann-La Roche
Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
Lumos Pharma
9-ING-41 in Patients With Advanced Cancers
Actuate Therapeutics Inc.
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
Eisai Inc.
AcceleRET-Lung
Hoffmann-La Roche
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Inhibrx Biosciences, Inc
A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors
AbbVie
MK-4830-001
Merck Sharp & Dohme LLC
A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
A Study of NX-1607 in Adults With Advanced Malignancies
Nurix Therapeutics, Inc.
RUBY
Tesaro, Inc.
LIVIGNO-3
AbbVie
A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)
ALX Oncology Inc.
MK-0482-001
Merck Sharp & Dohme LLC
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
DEKA Biosciences
CheckMate 7FL
Bristol-Myers Squibb
Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)
GlaxoSmithKline
Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers
Jazz Pharmaceuticals
IVY
Eli Lilly and Company
IO-001
iTeos Therapeutics
Dose-escalating, Safety, Tolerability and PK Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid Tumors
Taiho Oncology, Inc.
GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors
GlaxoSmithKline
Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer
Kyowa Kirin Co., Ltd.
A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer
Hoffmann-La Roche
SUMMIT
Puma Biotechnology, Inc.
A Study of ABT-165 in Subjects With Solid Tumors
AbbVie
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Sumitomo Pharma America, Inc.
CanStem43L
Sumitomo Pharma America, Inc.
A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer
Sumitomo Pharma America, Inc.
Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols
Sumitomo Pharma America, Inc.
MK-4440-001
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer
Amgen
Trybeca-1
ERYtech Pharma
MK-3475-434
Merck Sharp & Dohme LLC
A Phase 1 / 2 Dose Escalation Study of Locally-Administered OncoGelâ„¢ in Subjects With Recurrent Glioma
Boston Scientific Corporation
AVANA
Centus Biotherapeutics Limited
Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors
Genentech, Inc.
A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer
AbbVie
Safety and Tolerability of Oral LCL161 in Japanese Adult Patients With Advanced Solid Tumors
Novartis
A Trial of Oral BEZ235 and BKM120 in Combination With Paclitaxel With or Without Trastuzumab
Novartis
A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer
Novartis
A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel
Daiichi Sankyo
A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer
Quest PharmaTech Inc.
CS-7017 in Combination With Carboplatin/Paclitaxel in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)
Daiichi Sankyo
Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel
Bayer